Last edition
News about Market
STADA and Bio-Thera Secure EU Marketing Approval for Golimumab Biosimilar Gotenfia
European Commission authorises Gotenfia, referencing Simponi, for multiple autoimmune diseases across EU and EEA markets.
Market | 16/02/2026 | By News Bureau | 286
Lupin Posts 37 percent Q3 Profit Growth on Record US Sales
Lupin Limited reported a 37.4 percent year-on-year increase in net profit for the third quarter ended December 31, 2025, reaching INR 1,180.5 crore, compared with INR 858.9 crore in the same quarter last year.
Market | 13/02/2026 | By Darshana | 254
Pharma-to-Wellness Play: USV Secures Controlling Interest in Wellbeing Nutrition
USV has acquired a 79 percent stake in Wellbeing Nutrition, a leading consumer healthcare and nutrition company, in a deal valued at INR 1,583 crore. The acquisition marks a strategic move by USV to strengthen its presence in the fast-growing consumer wellness and nutrition segment.
Market | 12/02/2026 | By Darshana | 343
Iqvia and DCRI have formed a strategic collaboration to enhance the design and execution of obesity and cardiometabolic clinical trials, combining global operational capabilities with academic research expertise.
Market | 12/02/2026 | By News Bureau | 303
IOL Chemicals and Pharmaceuticals Reports Q3 and 9M FY26 Results
IOL Chemicals and Pharmaceuticals reported strong Q3 and nine-month FY26 results, with profit before exceptional items rising 39 percent year-on-year, supported by margin expansion and improved operational performance.
Market | 12/02/2026 | By News Bureau | 213
Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.
Market | 11/02/2026 | By News Bureau | 278
GSK's RSV Vaccine Arexvy Accepted for Regulatory Review in China for Adults Aged 60 and Above
China’s drug regulator has accepted GSK’s Arexvy for review to prevent RSV-related lower respiratory tract disease in adults 60 and older, with a decision expected in 2027.
Market | 11/02/2026 | By News Bureau | 320
Lupin Resolves Mirabegron Patent Dispute with Astellas in USD 90 Million Settlement
Lupin Limited has reached a USD 90 million settlement to resolve a patent dispute with Japan-based Astellas Pharma concerning Lupin’s generic version of mirabegron, a treatment for overactive bladder. The agreement concludes ongoing litigation in the United States and provides commercial clarity around Lupin’s continued participation in the market.
Market | 11/02/2026 | By Darshana | 195
Pandorum Technologies Raises USD 18 Million in Series B to Advance Regenerative Therapies
Pandorum Technologies has raised USD 18 million in a Series B funding round to accelerate the clinical development and global market access of its programmable tissue regenerative therapies, with expansion plans spanning the US, Asia and the Middle East.
Market | 11/02/2026 | By News Bureau | 257
Waters Completes Merger with BD's Biosciences and Diagnostic Solutions Businesses
Waters has completed its merger with BD’s Biosciences and Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader focused on high-volume testing in regulated applications, alongside announcing the appointment of Claire M Fraser, PhD, to its Board and the formation of four new operating divisions.
Market | 10/02/2026 | By News Bureau | 299
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy